



FOR IMMEDIATE RELEASE

## **Keraderm to Release \$100 Phototherapy Treatment for Fungal Nail Infections**

**Hampton, VA – September 17, 2008** – Keraderm, a leader in the development of phototherapy treatments for infections, plans to introduce a \$100 phototherapy treatment for fungal nail infections (onychomycosis) in 2009 upon completion of their current pivotal trials and pending marketing clearance from the FDA.

“Our goal,” states Keraderm CEO Bill Cumbie, “is to develop a safe and effective treatment for onychomycosis that can be accessed by a large number of people at a low cost. Many people cannot use current medications due to their high cost, significant side effects, and contraindications while taking other medications. Our pilot clinical trials have indicated the efficacy of the best oral medications with no significant side effects. We will establish the safety and efficacy of our treatment with our current pivotal clinical trials which will be submitted to the FDA for approval as the first phototherapy treatment for onychomycosis. The beauty of our treatment is that it can be delivered easily and inexpensively. We hope to introduce our treatment in 2009 at \$100 for several treatments and continue to improve the technology so that eventually only one treatment in the \$100 range will be necessary. We are also working to establish insurance reimbursement for our therapy which will further reduce cost to the consumer.”

Keraderm is well on the way to be the first phototherapy treatment approved by the FDA for onychomycosis with its research published in the prestigious peer-reviewed *British Journal of Dermatology* and presented at the 2007 World Congress of Dermatology and the 2008 Annual Conference of the American Academy of Dermatology. Keraderm also has a growing portfolio of national and international patents that protect the key aspects of its proprietary platform technology to treat infections.

### **About Keraderm**

Keraderm LLC is a medical device company with proprietary, patented, platform technology for a wide variety of infections. This technology has the potential to effectively treat infections without the serious side effects that many medications have and to effectively treat infections caused by drug resistant organisms such as MRSA. Keraderm has obtained patents on its key technologies to treat infections and has a number of additional patent applications pending on refinements of its technology. Published laboratory and clinical studies indicate that the technology has great potential to effectively and safely treat infections.

### **Forward looking statements**

Statements in this press release containing the words believe, may, expect, project and other similar expressions are forward looking statements that are not definite and have a number of risks and uncertainties. Representative factors that can cause actual results to differ from those projected include the following: regulatory clearance of products, market acceptance; financial constraints; government regulations; obtaining and enforcing intellectual property rights;



attracting and retaining key employees; developing partnership opportunities; timing of commercial product launches; and other similar internal and external risks factors.

**Media Contact:**

Bill Cumbie  
144 Research Drive  
Hampton, VA 23666  
(757) 344-8607  
[www.keraderm.com](http://www.keraderm.com)  
[bill@keraderm.com](mailto:bill@keraderm.com)

###